Your browser doesn't support javascript.
loading
Titin copy number variations associated with dominant inherited phenotypes.
Perrin, Aurélien; Métay, Corinne; Savarese, Marco; Ben Yaou, Rabah; Demidov, German; Nelson, Isabelle; Solé, Guilhem; Péréon, Yann; Bertini, Enrico Silvio; Fattori, Fabiana; D'Amico, Adele; Ricci, Federica; Ginsberg, Mira; Seferian, Andreea; Boespflug-Tanguy, Odile; Servais, Laurent; Chapon, Françoise; Lagrange, Emmeline; Gaudon, Karen; Bloch, Adrien; Ghanem, Robin; Guyant-Maréchal, Lucie; Johari, Mridul; Van Goethem, Charles; Fardeau, Michel; Morales, Raul Juntas; Genetti, Casie A; Marttila, Minttu; Koenig, Michel; Beggs, Alan H; Udd, Bjarne; Bonne, Gisèle; Cossée, Mireille.
Affiliation
  • Perrin A; Laboratoire de Génétique Moléculaire, Centre Hospitalier Universitaire de Montpellier, Montpellier, France mireille.cossee@inserm.fr aurelien.perrin@ext.inserm.fr.
  • Métay C; PhyMedExp, Université de Montpellier, INSERM, CNRS, Montpellier, France.
  • Savarese M; Unité Fonctionnelle de Cardiogénétique et Myogénétique moléculaire et cellulaire, Centre de Génétique Moléculaire et Chromosomique, Groupe Hospitalier La Pitié-Salpêtrière-Charles Foix, Paris, France.
  • Ben Yaou R; Sorbonne Université, INSERM, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
  • Demidov G; Tampere Neuromuscular Center, Folkhälsan Research Center, Helsinki, Finland.
  • Nelson I; Sorbonne Université, INSERM, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
  • Solé G; Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tubingen, Germany.
  • Péréon Y; Sorbonne Université, INSERM, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
  • Bertini ES; CHU de Bordeaux, AOC National Reference Center for Neuromuscular Disorders, Bordeaux, France.
  • Fattori F; Department of Clinical Neurophysiology, Reference Centre for Neuromuscular Diseases AOC, Filnemus, Euro-NMD, CHU Nantes, Nantes Université, Place Alexis-Ricordeau, Nantes, France.
  • D'Amico A; Unit of Muscular and Neurodegenerative Disorders, Bambino Gesù Children Research Hospital, IRCCS, Rome, Italy.
  • Ricci F; Unit of Muscular and Neurodegenerative Disorders, Bambino Gesù Children Research Hospital, IRCCS, Rome, Italy.
  • Ginsberg M; Unit of Muscular and Neurodegenerative Disorders, Bambino Gesù Children Research Hospital, IRCCS, Rome, Italy.
  • Seferian A; Division of Child and Adolescent Neuropsychiatry, University of Turin, Turin, Italy.
  • Boespflug-Tanguy O; Department of Pediatric Neurology, Wolfson Medical Center, Holon, Israel.
  • Servais L; Institut I-MOTION, Hôpital Armand Trousseau, Paris, France.
  • Chapon F; Institut I-MOTION, Hôpital Armand Trousseau, Paris, France.
  • Lagrange E; UMR 1141, INSERM, NeuroDiderot Université Paris Cité and APHP, Neuropédiatrie, French Reference Center for Leukodystrophies, LEUKOFRANCE, Hôpital Robert Debré, Paris, France.
  • Gaudon K; Institut I-MOTION, Hôpital Armand Trousseau, Paris, France.
  • Bloch A; MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Ghanem R; Neuromuscular Reference Center, Division of Paediatrics, University and Hospital University of Liège, Liège, Belgium.
  • Guyant-Maréchal L; Département de pathologie, Centre de Compétence des Maladies Neuromusculaires, Centre Hospitalier Universitaire de Caen, Caen, France.
  • Johari M; Centre de Compétences des Maladies Neuro Musculaires, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.
  • Van Goethem C; Unité Fonctionnelle de Cardiogénétique et Myogénétique moléculaire et cellulaire, Centre de Génétique Moléculaire et Chromosomique, Groupe Hospitalier La Pitié-Salpêtrière-Charles Foix, Paris, France.
  • Fardeau M; Unité Fonctionnelle de Cardiogénétique et Myogénétique moléculaire et cellulaire, Centre de Génétique Moléculaire et Chromosomique, Groupe Hospitalier La Pitié-Salpêtrière-Charles Foix, Paris, France.
  • Morales RJ; Unité Fonctionnelle de Cardiogénétique et Myogénétique moléculaire et cellulaire, Centre de Génétique Moléculaire et Chromosomique, Groupe Hospitalier La Pitié-Salpêtrière-Charles Foix, Paris, France.
  • Genetti CA; Department of Neurophysiology, Rouen University Hospital, Rouen, France.
  • Marttila M; Tampere Neuromuscular Center, Folkhälsan Research Center, Helsinki, Finland.
  • Koenig M; Harry Perkins Institute of Medical Research, Centre for Medical Research, University of Western Australia, Nedlands, Western Australia, Australia.
  • Beggs AH; Laboratoire de Génétique Moléculaire, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
  • Udd B; Montpellier BioInformatique pour le Diagnostic Clinique (MOBIDIC), Plateau de Médecine Moléculaire et Génomique (PMMG), CHU Montpellier, Montpellier, France.
  • Bonne G; Sorbonne Université, INSERM, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
  • Cossée M; Department of Neurology, Hospital Universitario Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
J Med Genet ; 61(4): 369-377, 2024 Mar 21.
Article in En | MEDLINE | ID: mdl-37935568
BACKGROUND: Titinopathies are caused by mutations in the titin gene (TTN). Titin is the largest known human protein; its gene has the longest coding phase with 364 exons. Titinopathies are very complex neuromuscular pathologies due to the variable age of onset of symptoms, the great diversity of pathological and muscular impairment patterns (cardiac, skeletal muscle or mixed) and both autosomal dominant and recessive modes of transmission. Until now, only few CNVs in TTN have been reported without clear genotype-phenotype associations. METHODS: Our study includes eight families with dominant titinopathies. We performed next-generation sequencing or comparative genomic hybridisation array analyses and found CNVs in the TTN gene. We characterised these CNVs by RNA sequencing (RNAseq) analyses in six patients' muscles and performed genotype-phenotype inheritance association study by combining the clinical and biological data of these eight families. RESULTS: Seven deletion-type CNVs in the TTN gene were identified among these families. Genotype and RNAseq results showed that five deletions do not alter the reading frame and one is out-of-reading frame. The main phenotype identified was distal myopathy associated with contractures. The analysis of morphological, clinical and genetic data and imaging let us draw new genotype-phenotype associations of titinopathies. CONCLUSION: Identifying TTN CNVs will further increase diagnostic sensitivity in these complex neuromuscular pathologies. Our cohort of patients enabled us to identify new deletion-type CNVs in the TTN gene, with unexpected autosomal dominant transmission. This is valuable in establishing new genotype-phenotype associations of titinopathies, mainly distal myopathy in most of the patients.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Distal Myopathies Limits: Humans Language: En Journal: J Med Genet Year: 2024 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Distal Myopathies Limits: Humans Language: En Journal: J Med Genet Year: 2024 Type: Article